Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

A randomised clinical trial of slow versus fast intravitreal injection of ranibizumab (Lucentis®) and its impact on intraocular pressure (the Speed IOP Study)

Samantha Fraser-Bell; Sophia Zagora; Hemal Mehta; Anna Campain; Hon Seng Wong; Yeung Aaron; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):79. doi:

ARVO Annual Meeting Abstract September 2016

Progression of Diabetic Retinopathy in the Bevordex study: a randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema

Lyndell L Lim; Dania Qatarneh; Lauren Hodgson; Hemal Mehta; Sanjeewa Wickremasinghe; Anna Campain; Mark C Gillies; Samantha Fraser-Bell

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2106. doi:

ARVO Annual Meeting Abstract June 2015

BEVORDEX - A multicentre randomized clinical trial of intravitreal dexamethasone versus intravitreal bevacizumab for persistent diabetic macular edema

Mark C Gillies; Lyndell L Lim; Anna E Campain; Hemal Mehta; Godfrey Quin; Samantha Fraser-Bell; Ian McAllister; Wedad Salem; Ji Li

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3144. doi:

ARVO Annual Meeting Abstract June 2015

Effects of Switching from Ranibizumab to Aflibercept on Visual Outcome, Lesion Activity and Treatment Intensity in Eyes with Neovascular Age-Related Macular Degeneration

Daniel Barthelmes; Anna E Campain; Jennifer J Arnold; Ian McAllister; Judy M Simpson; Alex P Hunyor; Robyn H Guymer; Rohan W Essex; Nigel Morlet; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4589. doi:

ARVO Annual Meeting Abstract April 2014

BEVORDEX - A multicentre randomized clinical trial of intravitreal bevacizumb versus intravitreal dexamethasone for persistent diabetic macular oedema.

Mark C Gillies; Lyndell L Lim; Anna Campain; Goff Quin; Wedad Salem; Ji Li; Stephanie Goodwin; Christine Aroney; Ian McAllister; Samantha Fraser-Bell

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5053. doi:

Advertisement